Literature DB >> 3876934

Induction of a 26-kDa-protein mRNA in human cells treated with an interleukin-1-related, leukocyte-derived factor.

J Content, L De Wit, P Poupart, G Opdenakker, J Van Damme, A Billiau.   

Abstract

A human-leukocyte-derived antiviral protein (22-kDa factor), known to be an inducer of interferon-beta (IFN-beta) in fibroblastoid cells, and to be closely related to interleukin-1 (IL-1), was shown to likewise act as inducer of the mRNA of a 26-kDa secreted protein. This protein was first described as the gene product of an mRNA that is co-induced with the mRNA of IFN-beta by superinduction of fibroblasts (treatment with dsRNA and cycloheximide). Subsequently it was shown to be induced by treatment with cycloheximide only. The 22-kDa factor induced high levels of the 26-kDa-protein mRNA and low levels of IFN-beta mRNA. Addition of cycloheximide to the 22-kDa factor resulted in further significant increases in mRNA levels for both the 26-kDa-protein and IFN-beta. These observations add to the evidence already available that transcription of the genes for IFN-beta and the 26-kDa-protein are differently regulated. The observation that a factor that belongs to the IL-1 family induces the 26-kDa-protein suggest that the latter plays a role as an intermediary or effector molecule in inflammatory or immunoregulatory processes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876934     DOI: 10.1111/j.1432-1033.1985.tb09191.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  45 in total

1.  Aberrant cytokine production from tenosynovium in dialysis associated amyloidosis.

Authors:  N Miyasaka; K Sato; Y Kitano; M Higaki; K Nishioka; K Ohta
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

Review 2.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

3.  Leukotriene B4 up-regulates IL-6 rather than IL-1 synthesis in human monocytes.

Authors:  P E Poubelle; J Stankova; J Grassi; M Rola-Pleszczynski
Journal:  Agents Actions       Date:  1991-09

4.  Role of interleukin 6 in epithelial hyperproliferation and bone resorption in middle ear cholesteatomas.

Authors:  J Bujía; C Kim; P Ostos; E Kastenbauer; L Hültner
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

5.  Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

Authors:  A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence.

Authors:  Y H Zhang; J X Lin; J Vilcek
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

Review 7.  The role of tumor necrosis factor and interleukin 1 in the immunoinflammatory response.

Authors:  J W Larrick; S L Kunkel
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

8.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

9.  Mediators of microvascular injury in dermal burn wounds.

Authors:  Z B Ravage; H F Gomez; B J Czermak; S A Watkins; G O Till
Journal:  Inflammation       Date:  1998-12       Impact factor: 4.092

Review 10.  Host defense against infections and inflammations: role of the multifunctional IL-6/IFN-beta 2 cytokine.

Authors:  M Revel
Journal:  Experientia       Date:  1989-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.